Clinical Trials Logo

DS Stage II Plasma Cell Myeloma clinical trials

View clinical trials related to DS Stage II Plasma Cell Myeloma.

Filter by:

NCT ID: NCT00839956 Active, not recruiting - Clinical trials for DS Stage II Plasma Cell Myeloma

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

Start date: February 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of giving bortezomib together with vorinostat and to see how well it works in treating patients with multiple myeloma who have undergone autologous stem cell transplant. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat after an autologous stem cell transplant may stop the growth of any cancer cells that remain after transplant.

NCT ID: NCT00445692 Completed - Clinical trials for Refractory Plasma Cell Myeloma

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Start date: January 10, 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies lenalidomide, dexamethasone, and clarithromycin in treating patients who have undergone stem cell transplant for multiple myeloma. Biological therapies, such as lenalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone and clarithromycin may be an effective treatment for multiple myeloma.

NCT ID: NCT00088855 Completed - Clinical trials for DS Stage II Plasma Cell Myeloma

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

Start date: June 15, 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well bortezomib and pegylated liposomal doxorubicin hydrochloride work in treating patients multiple myeloma that are experiencing symptoms and have not received prior treatment. Bortezomib and pegylated liposomal doxorubicin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00066638 Completed - Clinical trials for Refractory Plasma Cell Myeloma

FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Start date: June 2003
Phase: Phase 2
Study type: Interventional

Drugs used in chemotherapy such as FR901228 use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of FR901228 in treating patients who have relapsed or refractory multiple myeloma